A study to compare effectiveness amongst two drugs ,one is injection desferoxamine with tablet deferasirox as a chelator in thalassemia patients

A Comparative Trial To Assess The Efficacy Of Tablet Deferasirox Versus Injection Deferoxamine By Reduction In Serum Ferritin Level In Pediatric Thalassemia Major Patient In Tertiary Care Hospital By Prospective Study.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/08/009441

Enrollment

Registered

2017-08-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- THALASEMIA PATIENTS OF AGE GROUP 3 YEAR TO 18 YEARS

Interventions

Control Intervention1: TABLET DEFERASIROX injection DEFEROXAMINE: Tablet wil be given in dose 15-40 mg/kg/day everyday for 6months per oral Injection will be given in dose 20-40 mg/kg/dose 2 hours af

Eligibility

Inclusion criteria

Inclusion criteria: 1 Thalassemia major Patients 2 Pediatric age group 3 years to 18 years 3 On regular Deferasirox Therapy 4 Serum ferritin more than 1000mg/dl 5 With positive consent for study

Exclusion criteria

Exclusion criteria: 1 Pt 2 Pt > 18years 3 Patient with negative consent 4 Renal failure 5 Cataract 6 Ototoxicity HIV positive Hepatitis B positive Av block Asthma On going infection( temporary exclusion included on recovery) Severe allergy

Design outcomes

Primary

Measure	Time frame
To measure consecutive serum ferritin level in Participant with Î² Thalassemia major every 2 month with ongoing dosage of iron chelators ,admitted in Paediatric ward sir T hospital BhavnagarTimepoint: 6 months	—

Secondary

Measure	Time frame
THE VELOCITY IN DECREASING SERUM FERRITIN IN INJECTION CHELATOR IS BETTER THAN ORAL FORMTimepoint: 6 MONTHS	—

Countries

India

Contacts

Public Contactratna d bhojak

sir takhtasihnji general hospital bhavnagar

jayendragohil@gmail.com7874322722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026